MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug- …

… financial results for its third quarter ended September 27, 2025 … .” Third Quarter 2025 Results Net sales for the third quarter of … a leading online pet pharmacy, in its family of … , 2025   September 28, 2024 Capital Expenditures (millions):               New …

West Pharmaceutical Services, Inc. (NYSE:WST) Q3 2025 Earnings Call … guidance. As Eric mentioned, third quarter revenue was $805 million, … 210 million in capital expenditures and remain on track … had a very solid third quarter operationally that exceeded our …

… of a surge in pharmaceutical production. Excluding biomedical manufacturing … the ongoing AI capital expenditure boom which has “supercharged … per cent, and said third-quarter GDP growth is expected … been feared in the third quarter. “The electronics cluster …

…   GROWTH IN EUR MILLION Q3 2025 Q3 2024 CHANGE ORGANIC SCOPE CURRENCY …   › Robust third quarter revenue   In the third quarter of 2025, Bureau … be balanced between Capital Expenditure (Capex), Mergers … contract for a pharma company, providing specialized …

… Thermo Fisher Scientific 2025 Third Quarter Conference Call. My name … an overview of our third quarter results for the total … billion of net capital expenditures. Q3 was a very active quarter … , on MFNs between the pharmaceutical companies, and the industry …

… Health (MOH) through the Pharmacy Division. With the cut … especially as government’s third quarter expenditures are being aggregated. What … government is collating its Q3 spending to prepare for … government is consolidating its Q3 spending to prepare for …

… (META) will report third-quarter results late Wednesday. Analysts … 72 billion on capital expenditures this year. Earlier … ABBV) will report their third-quarter results this coming week … ) and Alnylam Pharmaceuticals (ALNY) will report Q3 results early Thursday …

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that Mala Murthy will be stepping down from her role as Chief Financial Officer to pursue an opportunity outside of the healthcare …

… strong performance in the third quarter of 2025 by its … global manufacturing requirements.” In Q3, Lonza saw “strong momentum” … in Q3 supported by higher volumes in its pharmaceutical capsules … first phase of capital expenditure progressing as planned, Lonza …